AZ CEO: No settlement on generics

Will AstraZeneca settle with generics makers challenging its blockbuster meds Nexium and Seroquel? Fuhgeddaboutit, says CEO David Brennan (photo). "We are going to vigorously defend our intellectual property in the judicial process," Brennan told reporters, saying that the company has won seven out of eight patent disputes in the past. The message? Brennan thinks AstraZeneca can win.

But at the same briefing, Brennan appeared to be hedging his bets. "Obviously, we have options available to us," he said. "We always explore options that are available." The company also has contingency plans: if Nexium and/or Seroquel fall to generics competition--which could happen as soon as next month--AstraZeneca would quickly cut more costs.

- check out this story from CNBC
- see the item at Pharmalot

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.